Published on 9 Nov 2023 on GuruFocus.com via Yahoo Finance
Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress
Repare Therapeutics Inc (NASDAQ:RPTX) presented promising initial data from the Phase 1 MYTHIC clinical trial.The company reported a decrease in revenue from collaboration agreements compared to Q3 2022.Net R&D expenses increased due to the advancement of lunresertib clinical program and preclinical studies.Repare Therapeutics Inc (NASDAQ:RPTX) expects to fund its operations into 2026 with current cash reserves.
Warning! GuruFocus has detected 4 Warning Signs with RPTX.
On November 9, 2023, Repare Therapeutics Inc (NASDAQ:RPTX), a clinical-stage precision oncology company, released its financial results for the third quarter ending September 30, 2023. The company highlighted significant progress in its clinical pipeline, particularly with the Phase 1 MYTHIC trial evaluating lunresertib, and provided updates on its preclinical programs.